493 results on '"Follo, Matilde"'
Search Results
2. Molecular taxonomy of myelodysplastic syndromes and its clinical implications
3. The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
4. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
5. Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression
6. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
7. Advances in MDS/AML and inositide signalling
8. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies
9. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
10. Nuclear Phospholipids and Signaling: An Update of the Story
11. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study
12. Inositide-Dependent Nuclear Signalling in Health and Disease
13. Recent advances in MDS mutation landscape: Splicing and signalling
14. Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells
15. Nuclear Phospholipids and Signaling: An Update of the Story.
16. Metformin influences drug sensitivity in pancreatic cancer cells
17. Nuclear inositide signaling and cell cycle
18. Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
19. Nuclear Phosphoinositides as Key Determinants of Nuclear Functions
20. PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis
21. Inositide-Dependent Nuclear Signalling in Health and Disease
22. Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes
23. Supplementary Table S1 from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes
24. Supplementary Figure S2 from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes
25. Microbiota-Gut-Brain Axis in Neurological Disorders: From Leaky Barriers Microanatomical Changes to Biochemical Processes
26. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
27. TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutive history of multiple myeloma
28. Nuclear shape instability caused by lamin A deregulation promotes invasiveness in pediatric bone sarcomas: from nucleo-cytoskeleton dynamics to novel therapeutic opportunities
29. Modulation of nuclear PI-PLCbeta1 during cell differentiation
30. DNA Methylation Profiles Capture Clinical and Molecular Heterogeneity of MDS and Can be Harnessed for the Development of Robust Biomarkers Predictive of Response to Azacitidine
31. Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
32. Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes
33. Nuclear Phosphoinositides: Location, Regulation and Function
34. Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics
35. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies
36. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
37. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
38. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy
39. Meet the Editorial Board Member
40. The physiological roles of primary phospholipase C
41. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
42. Reduction of Phosphoinositide-Phospholipase C Beta1 Methylation Predicts the Responsiveness to Azacitidine in High-Risk MDS
43. Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma
44. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53
45. Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes
46. “Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia”
47. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
48. Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia
49. Unravelling Heterogeneity of Amplified Human Amniotic Fluid Stem Cells Sub-Populations
50. Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.